Author: xingxuhui

Targeted therapy in breast cancer focuses on specific molecular markers like HER2, hormone receptors (HR), or mutations (e.g., ESR1, PIK3CA), guiding treatments for better outcomes with fewer side effects. In 2025, indications are based on tumor subtype, stage, and biomarkers—key breakthroughs from ASCO and ESMO expand options for HR-positive, HER2-positive, and triple-negative cases. This educational overview draws from clinical guidelines; consult your oncologist for testing and eligibility.

Christmas gatherings bring families and friends together across the US, from cozy living rooms in the Midwest to festive tables in California homes. Delicious desserts add joy to these moments, but busy schedules leave little time for complicated baking. These 5 easy-to-make treats use everyday ingredients, take just minutes to prepare, and look impressive on any holiday spread. Perfect for potlucks, office parties, or quiet evenings by the tree, they combine classic flavors with quick steps. Gather supplies from local stores like Walmart or Target, and create memorable sweets without hours in the kitchen.

In 2025, breast cancer research in the US has accelerated with promising advancements in targeted therapies, immunotherapies, and innovative delivery methods, potentially improving outcomes for hormone-positive, HER2-positive, and triple-negative subtypes. Highlights from trials like DESTINY-Breast09 and ASCENT-04 offer hope for better progression-free survival and reduced recurrence risks—this overview is based on recent clinical data; always discuss with your oncologist for personalized care.